Skip to main content

COVID 19 Updates from RheumNow

FDA Hearing on COVID-19 Vaccines

Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Remdesivir FDA Approved for Hospitalized COVID-19

The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

Clinical Trial Boom or Bust in Severe COVID-19

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.


Outpatient Visits Return to Pre-COVID Rates

The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Dr. Jack Cush sings the news and journal reports from the past week on 

COVID Transmission from Young to Old

The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.

Hydroxychloroquine Shows No Benefit in Hospitalized COVID-19 Patients

The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.

RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)

Dr. Jack Cush Reviews the news and journal articles from the past week on

Systemic Steroids Reduce Mortality in COVID-19

JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.

RheumNow Podcast – Function Follows Form (10.2.20)

Dr. Jack Cush reviews the news and journal articles from the past week on 

Hydroxychloroquine Fails as Pre-exposure Prophylaxis for COVID-19

Numerous previous studies have questioned the efficacy or protection afforded by hydroxychloroquine (HCQ) for COVID-19 and studies have show that HCQ has failed when given as post-exposure prophylaxis to health care workers (HCWs).  A new randomized controlled trial has shown that HCQ failed when


Pre Print of UK research suggests biomarkers for Severe COVID-19 includes markers of myeloid or endothelial activation; such as D-dimer, EN-RAGE, CXCL10, GM-CSF, IL-6, TNF-α, IL-2, GDF-15, G-CSF, S100A12,

Dr. John Cush RheumNow( View Tweet)

1 week 1 day ago
There have been many cases of Kawasaki vasculitis in kids ith COVID-19; now Lg vessel vasculitis in 79 yo Japanese man w/ COVID-19 pneumonia, CRP 17.7 mg/dL, spiking fevers and CTA and FDG-PET evid of aortic and LVV, neg ANCA, nl IgG4, but was HLA-DR4+.

Dr. John Cush RheumNow( View Tweet)

1 week 3 days ago
Observational study of 123 Spanish rheumatic dz pts w/ COVID-19, finds 54 hospitalized. Admitted pts were 69.7 yrs, and 22% died. Admission was assoc w/ older age, autoimmune dz (vs inflammatory arthritis; OR: 3.55), but not DMARD Rx.

Dr. John Cush RheumNow( View Tweet)

1 week 4 days ago
The RheumNow Podcast is up - Bad Disease & Bad Outcomes. COVID consequences, TNFi Switching in SpA, psychosis in lupus? Watch it here> or listent to podcast on iTunes> or SoundCloud>

Dr. John Cush RheumNow( View Tweet)

1 week 6 days ago
Another case of COVID-19 Arthritis; 58 yoF w/ non-severe COVID-19, (by qRT-PCR ) had arthralgia, fever, cough, nausea, diarrhoea, dysgeusia, and devloped ankle arthritis CRP 7·36 mg/L, lymphopenia (1·29) persistent arthritis (by US) and +Sars-CoV-2 in SF.

Dr. John Cush RheumNow( View Tweet)

2 weeks 1 day ago
Comparison of 34,128 COVID and 84,585 influenza pts; COVID-19 patients have been more typically been male, younger, and have fewer comorbidities and lower medication use than flu. (data from USA, South Korea, Spain)

Dr. John Cush RheumNow( View Tweet)

2 weeks 2 days ago
To quash the virus, the immune system unleashes an arsenal. Sometimes these weapons turn inward and destroy healthy tissues. Combatting this friendly fire has become as crucial a part of the Covid-19 treatment strategy as subduing the virus itself.

NYT Health NYTHealth( View Tweet)

2 weeks 4 days ago
Adam Cifu adamcifu( View Tweet)
2 weeks 4 days ago
Latest data Global Rheumatology Alliance COVID Registry -2121 pts (40% RA, 17% SLE, 9% PsA), 64% on DMARDs, 33% biologics, 5% JAKi, 34% steroid,27% HCQ, with only 7.6 deaths and 39% hospitalized and 81% resolved infection.

Dr. John Cush RheumNow( View Tweet)

3 weeks 2 days ago
Swiss cohort of 666 axSpA, RA & PsA pts seen before, during & after COVID; consults dropped 52%, remote visits increased 129%, & non-compliance slightly increased during COVID (axSpA 20% vs 13% before, p=0.003); but no incr in flares(<15%) or Dz activity

Dr. John Cush RheumNow( View Tweet)

3 weeks 2 days ago